PARKINSONS (MILD TO MODERATE) Tx-MAO B INHIBITOR

SUMMARY

1. MAO-B inhibitor selegiline delays the need for L-dopa in patients with mild PD by 9 months by reducing oxidative damage in the substantia nigra & slowing the disease progression.

2. Some evidence that rasagiline may also slow decompensation in early Parkinson disease.

3. No treatment for PD has been proven to be "neuroprotective."

4. Combining selegiline with tricyclics or SSRIs can potentially cause the serotonin syndrome.

Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].